VistaGen Therapeutics: Buy Rating Backed by Promising Clinical Trials and Stable Financial Outlook
VistaGen Therapeutics received a Buy rating from analyst Jason McCarthy of Maxim Group, with a $12 price target. The rating is supported by promising Phase 3 clinical trials for fasedienol in social anxiety disorder and a stable financial outlook, with $77.2 million in cash to support operations through mid-2026. The company aims for a New Drug Application submission, with commercialization expected by FY28. The valuation model includes revenue risk adjustments and a 25% discount rate, reflecting confidence in VistaGen's growth potential.
VistaGen Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $12.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy has given his Buy rating due to a combination of factors related to VistaGen Therapeutics’ ongoing clinical trials and financial outlook. The company is progressing with its Phase 3 PALISADE-3 and PALISADE-4 studies for fasedienol in social anxiety disorder, with key data readouts expected by the end of 2025 and the first half of 2026, respectively. The successful outcome of these trials, particularly following the positive results from the previous PALISADE-2 study, could position VistaGen for a New Drug Application submission, enhancing the company’s prospects.
Additionally, VistaGen’s financial position appears stable, with $77.2 million in cash expected to support operations through mid-2026, covering the period for the top-line results from both ongoing studies. The valuation model anticipates the commercialization of fasedienol by FY28, with a calculated 12-month price target of $12, factoring in revenue risk adjustments and a 25% discount rate. These elements collectively contribute to the Buy rating, reflecting confidence in the company’s potential for growth and successful drug development.
